BACKGROUND Pulmonary hypertension (PH) is hemodynamically classified as pre-capillary (as seen in idiopathic
H eart failure with preserved ejection fraction (HFpEF) is frequently accompanied by pulmonary hypertension (PH), which is associated with a poor outcome. Recent studies have suggested that PH is found in 36% to 83% of patients with HFpEF (1-3) and that both elevated pulmonary artery pressure and right ventricular (RV) dysfunction are independent predictors of death in patients with HFpEF (1, (4) (5) (6) .
Hemodynamically, pre-capillary PH-characterized by a mean pulmonary arterial wedge pressure (PAWP) #15 mm Hg-is distinguished from postcapillary PH, as indicated by a PAWP >15 mm Hg (7) (8) (9) (10) (11) . The classic example of a disease characterized by pre-capillary PH is idiopathic pulmonary arterial hypertension (IPAH), which is caused by an obliterative pulmonary vasculopathy affecting predominantly small pulmonary arterioles. In contrast, left heart disease, such as HFpEF, causes post-capillary PH due to backward transmission of elevated leftsided filling pressures into the pulmonary circulation.
The latter group may present with isolated postcapillary PH or combined post-capillary PH with a pre-capillary component, as indicated by an elevated diastolic pressure gradient and/or an increased pulmonary vascular resistance (PVR) (8, 11, 12) .
Despite these seemingly clear definitions, a growing number of patients with PH are identified in whom criteria from multiple PH categories exist simultaneously. For example, several registries have documented a change of phenotype in patients diagnosed with IPAH, associated with increasing age (13, 14) . A significant number of these patients have a comorbidity profile typically found in patients with HFpEF, such as arterial hypertension, obesity, diabetes, and atrial fibrillation (15) .
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METHODS
An ongoing, investigator-initiated, noninterventional, Baseline characteristics were different between the 3 groups ( Table 1) . By definition, PAWP was higher in patients with PH-HFpEF, resulting in lower mean transpulmonary pressure gradient (TPG) and PVR compared with the other groups. Notably, right atrial pressure was considerably higher in patients with PHHFpEF (13 AE 5 mm Hg) compared with typical IPAH (9 AE 5 mm Hg; p < 0.001) and atypical IPAH (9 AE 5 mm Hg; p < 0.001).
In the PH-HFpEF group, mean TPG was 26 AE 9 mm Hg, and the vast majority of these patients (201 of 226; 89%) had a TPG >12 mm Hg. Furthermore, mean PVR was elevated at 7.0 AE 3.4 Wood units (WU),
indicating Cpc-PH (10).
TREATMENT CHARACTERISTICS. As per inclusion criteria, all patients in the COMPERA registry received at least 1 targeted PH therapy. However, the treatment patterns differed significantly between the 3 groups ( Table 2) 
Pulmonary Hypertension in Heart Failure During follow-up, the preference for PDE5i therapy in PH-HFpEF persisted ( Table 2) . At 1 year, 84% of the typical patients with IPAH received PDE5is, whereas 48% were treated with ERAs and 6% with PCAs. Patients with atypical IPAH showed similar preference patterns, but for patients with PH-HFpEF, there was significantly less use of ERAs (p < 0.001 vs. typical
Combination therapy was initiated within 3 months after diagnosis in 18% of the patients with typical IPAH compared with only 8% of those with atypical IPAH and 3% of the patients with PH-HFpEF.
At 1 year, combination therapy was used in 44% of the typical IPAH group, whereas the corresponding numbers for atypical IPAH and PH-HFpEF were 26%
and 7%, respectively ( Table 2) .
As shown in Table 3 , treatment discontinuation of PDE5i occurred significantly more often in patients with PH-HFpEF than with typical IPAH (18.4% vs.
8.8%; p ¼ 0.005), and patients with atypical IPAH were in between at 13%. The main reasons for discontinuation in patients with PH-HFpEF were side effects in 5.3% and lack of efficacy in 10%, the latter being less frequently observed (<3%) in the other groups. Values are n (%) or n. *Including switch to riociguat. †Including withdrawal of sitaxentan. Tables 1 and 2 . Values are median (interquartile range), mean AE SD, or %. Data shown on 6-min walking distance (6MWD) at baseline (on the basis of n ¼ 324 for typical IPAH, n ¼ 105 for atypical IPAH, and n ¼ 184 for PH-HFpEF), at 12 months (on the basis of n ¼ 126 for typical IPAH, n ¼ 38 for atypical IPAH, and n ¼ 46 for PH-HFpEF), and change from baseline (on the basis of n ¼ 111 for typical IPAH, n ¼ 29 for atypical IPAH, and n ¼ 40 for PH-HFpEF); WHO-FC at baseline (on the basis of n ¼ 407 for typical IPAH, n ¼ 136 for atypical IPAH, and n ¼ 225 for PH-HFpEF), at 12 months (on the basis of n ¼ 177 for typical IPAH, n ¼ 65 for atypical IPAH, and n ¼ 87 for PH-HFpEF), and % improvement (on the basis of n ¼ 174 for typical IPAH, n ¼ 65 for atypical IPAH, and n ¼ 87 for PH-HFpEF); and % changes from baseline to 12 months in plasma levels of natriuretic peptide serum levels (NT-proBNP or BNP, respectively; on the basis of n ¼ 115 for typical IPAH, n ¼ 47 for atypical IPAH, and n ¼ 42 for PH-HFpEF).
Abbreviations as in
Abbreviations as in Table 1 . targeted therapies in all 3 populations, with the greatest improvements seen in patients with typical IPAH, the least improvements in patients with PHHFpEF, and atypical IPAH again in between. With respect to side effects and tolerability of PH medications, differences between the 3 groups emerged. In patients with typical IPAH, side effect profile and drug tolerability matched data reported from clinical studies (17) . In patients with PH-HFpEF, targeted therapies, particularly ERAs, were less well tolerated.
Here, the drug discontinuation rate due to side effects or lack of efficacy reached 34% for ERA and 16% for PDE5i therapy. In atypical PAH, drug discontinuation rates were between those of typical IPAH and PHHFpEF.
PH in association with left heart disease is arguably severe PH contributed to their higher mortality.
This notion was supported by the fact that PH and right heart failure were listed as cause of death in 32%
of the patients with PH-HFpEF in our series.
Our data supported the hypothesis that there may be a disease continuum ranging from typical IPAH through atypical IPAH to PH-HFpEF (Central factors for left heart disease, that is, atypical IPAH (16, 17) . Interestingly, the analysis of the 2 groups ("original" vs. "restricted" inclusion criteria) supported our findings, as it described a similar shift in age and comorbidity profile with comparable hemodynamics. As in our study, patients with atypical IPAH in the AMBITION trial did respond to PH therapies, although the response was attenuated and the rate of treatment discontinuations was higher (17) . Various factors and comorbidities appear more or less frequently in patients with typical idiopathic pulmonary arterial hypertension (IPAH), defined as <3 risk factors for left heart disease; in patients with atypical IPAH ($3 risk factors); and in patients with PH-heart failure with preserved ejection fraction (HFpEF). Given the patterns and tendencies seen, is there a disease continuum ranging from typical IPAH through atypical IPAH to PH-HFpEF? AF ¼ atrial fibrillation; CAD ¼ coronary artery disease; Pulmonary Hypertension in Heart Failure
